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In Brief
In diabetes, glucagon secretion is
dysregulated but the underlying
mechanisms are not fully understood.
Knudsen et al. report that hyperglycemia
impairs glucagon secretion by SGLT-
dependent elevation of intracellular Na+,
leading to acidification, reduced ATP
production, and dysregulated KATP
channel activity in a cells. The SGLT
mechanism may also impair heart and
kidney cell ATP production.c.
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Diabetes is a bihormonal disorder resulting from
combined insulin and glucagon secretion defects.
Mice lacking fumarase (Fh1) in their b cells (Fh1bKO
mice) develop progressive hyperglycemia and dysre-
gulated glucagon secretion similar to that seen in
diabetic patients (too much at high glucose and too
little at low glucose). The glucagon secretion defects
are corrected by low concentrations of tolbutamide
and prevented by the sodium-glucose transport
(SGLT) inhibitor phlorizin. These data link hypergly-
cemia, intracellular Na+ accumulation, and acidifica-
tion to impaired mitochondrial metabolism, reduced
ATP production, and dysregulated glucagon secre-
tion. Protein succination, reflecting reduced activity
of fumarase, is observed in a cells from hyperglyce-
mic Fh1bKO and b-V59M gain-of-function KATP
channel mice, diabetic Goto-Kakizaki rats, and pa-
tients with type 2 diabetes. Succination is also
observed in renal tubular cells and cardiomyocytes
from hyperglycemic Fh1bKO mice, suggesting that
the model can be extended to other SGLT-express-
ing cells and may explain part of the spectrum of dia-
betic complications.
INTRODUCTION
Plasma glucose concentrations are maintained by a tug-of-war
between the hypoglycemic effect of insulin and the hyperglyce-
mic effect of glucagon. Under normal conditions, plasma
glucose in humans is maintained at 5 mM. The benefits of
good glycemic control in diabetic patients are well known: it pre-430 Cell Metabolism 29, 430–442, February 5, 2019 ª 2018 The Auth
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athy (Cryer, 2014).
Type 2 diabetes (T2D) results from a combination of insuffi-
cient insulin secretion and defective glucagon secretion and cul-
minates in hyperglycemia (Unger and Orci, 2010). T2D affects
every cell of the body, which explains the broad range of compli-
cations, including accelerated cardiac and renal failure (Forbes
and Cooper, 2013). Dysregulated glucagon secretion in T2D
manifests as over-secretion under hyperglycemic conditions
but insufficient release under hypoglycemic conditions (Dunning
et al., 2005; Rorsman et al., 2014). If not alleviated, hypoglycemia
results in glucose deficiency in the brain, coma, and ultimately
death. In normal situations, hypoglycemia triggers a counter-
regulatory response in the a cells (stimulation of glucagon
release with resultant increase in hepatic glucose production),
but this does not occur in many type 1 diabetes (T1D) and
some T2D patients (Cryer, 1998). Patients with T1D experience
on average two episodes of symptomatic hypoglycemia every
week (Frier, 2009), and it has been estimated that up to 10% of
these patients die of iatrogenic hypoglycemia (Skrivarhaug
et al., 2006). Therefore, hypoglycemia has been referred to as
the limiting factor in diabetes therapy (Cryer, 2002).
Why counter-regulation fails in diabetic patients is not known,
but, interestingly, inhibition of mitochondrial ATP production, or
pharmacological activation of KATP channels using diazoxide, re-
capitulates the dysregulation of glucagon secretion (Zhang et al.,
2013). Collectively, these observations suggest that the
glucagon secretion defect in diabetic patients is a consequence
of disturbed mitochondrial metabolism, but the underlying
mechanisms remain obscure.
b cell-specific ablation of the gene encoding the Krebs cycle
enzyme fumarase in mice (designated Fh1bKO) results in pro-
gressive diabetes. Fh1bKO mice are born normoglycemic and
remain so for approximately 8 weeks. Thereafter, they develop
hyperglycemia due to loss of glucose-induced insulin secretion
(Adam et al., 2017). Here we show that the age-dependent lossor(s). Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
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Figure 1. Dysregulation of Glucagon Secre-
tion in Fh1bKO Mice
(A) Glucagon secretion in isolated islets from control
(CTL; black) and normoglycemic (plasma glucose:
<12 mM; gray) and diabetic (plasma glucose:
>20 mM; red) Fh1bKO mice at 1 and 6 mM glucose.
*p < 0.05 versus 1 mM glucose; #p < 0.05 versus
1 mM glucose in normoglycemic Fh1bKO islets (n =
8–9 experiments using islets from 12 mice).
(B) Islet glucagon content in normoglycemic and hy-
perglycemic Fh1bKO mice. *p < 0.05 (n = 12 mice of
each group, each measurement based on 12 islets).
(C) Immunohistochemistry (IHC) for succination
(2SC) in CTL and Fh1bKO islets. Scale bar, 50 mm.
(D) Plasma fumarate levels in CTL and severely hy-
perglycemic (>20 mM) Fh1bKO mice (n = 22 CTL
and n = 13 Fh1bKO mice).
(E and F) Glucagon secretion in isolated islets from
wild-type (NMRI) islets at 1 and 20 mM glucose and
supplementing the extracellular medium with 5 mM
Na2-fumarate (E; n = 4 experiments using islets from
three mice), or 5 mM dimethyl (dm)-fumarate (F; n =
12 experiments using islets from four mice). *p <
0.05 versus 1 mM glucose; #p < 0.05 versus 20 mM
glucose.
All data presented as mean values ± SEM of indi-
cated number of experiments. See also Figure S1.of insulin secretion is paralleled by dysregulation of glucagon
secretion similar to that in T2D.Similar defects in glucagon secre-
tion develop in other diabetic models: transgenic mice that
express a human neonatal diabetes mutation (Kir6.2-V59M) spe-
cifically in b cells (Brereton et al., 2014) and Goto-Kakizaki (GK)
rats, a model of polygenic diabetes (Granhall et al., 2006).
We have explored the mechanism underlying hyperglycemia-
induced dysregulation of glucagon secretion and our data high-
light a critical role for Na+-glucose co-transport (SGLT)-mediated
Na+ uptake and intracellular acidification. We propose that this
concept may be extended to other cell types and explain part
of the spectrum of diabetes-associated complications.
RESULTS
Dysregulation of Glucagon Secretion in Fh1bKO Mice
Mice lacking Fh1 in pancreatic b cells (Fh1bKO) are almost nor-
moglycemic until 10–13 weeks of age (10 weeks in male and
13weeks in female mice), when they exhibit a rapid and progres-
sive deterioration of glucose homeostasis and insulin secretion
(Figures S1A–S1C) (Adam et al., 2017).
We compared glucagon secretion in islets isolated from
normo- and hyperglycemic Fh1bKO mice. In islets from normo-
glycemic Fh1bKO mice, the effects of glucose on glucagon
secretion were almost identical to those seen in littermate con-
trols (CTLs) (Figure 1A). In these non-diabetic mice, glucagon
secretion was high at 1 mM glucose and inhibited by >60%
when glucose was elevated to 6 mM (the concentration associ-
ated with maximal inhibition of glucagon release; Walker et al.,
2011). However, once hyperglycemia had presented, glucagon
secretion at 1 mM glucose was reduced by 60% and elevation
of glucose exerted no further inhibitory effect. The reduction of
glucagon secretion at 1 mM glucose is remarkable given that
glucagon content was increased by 150% in Fh1bKO isletscompared with CTL islets (Figure 1B). The increase in content
is most likely due to an increase by 150% in the proportion of
a cells within islets (61% ± 2% cells/islet in hyperglycemic
Fh1bKO versus 25% ± 2% cells/islet in CTLs; n = 20 islets
from five mice per group; p < 0.001). Thus, glucagon secretion
at 1 mM glucose relative to glucagon content is reduced
by >80% (from 0.33%/hr to 0.06%/hr). In a separate experi-
mental series, we varied glucose between 2 and 20 mM (Fig-
ure S1D). Under these conditions, glucagon secretion at 2 mM
glucose was reduced by 75% in hyperglycemic Fh1bKO mice
compared with CTL mice, and, paradoxically, elevation of
glucose stimulated rather than inhibited glucagon secretion,
similar to the response of human islets from T2D patients at
this high glucose concentration (Walker et al., 2011).
Fumarase catalyzes the hydration of fumarate to malate, and
its genetic ablation results in a dramatic increase in intracellular
fumarate content (Pollard et al., 2003). Fumarate can react with
cysteine residues in proteins to form S-[2-succino]cysteine
(2SC), a stable post-translational modification termed succina-
tion (Frizzell et al., 2011).We investigated the levels of succination
in islets from Fh1bKO by immunohistochemistry with the 2SC
antibody. As expected, there was strong 2SC staining in the
b cells. However, some succination (albeit lower than in b cells)
was also observed in the non-b cells (arrow, Figure 1C; see also
Figure 6D). Thus, b cell-specific knockout of Fh1 also results in
elevated fumarate levels in a cells (which are genetically normal).
Plasma fumarate levels were not elevated in hyperglycemic
Fh1bKOmice (Figure 1D). Moreover, culturing of wild-type islets
with exogenous Na2-fumarate for 24 hr did not mimic the effect
on glucagon secretion of ablating Fh1 in b cells (Figure 1E). Thus,
the dysregulation of glucagon secretion in hyperglycemic
Fh1bKO mice is unlikely to result from ‘‘leakage’’ of fumarate
from b cells. However, in islets incubated with membrane-
permeable dimethyl-fumarate, glucose not only failed to inhibitCell Metabolism 29, 430–442, February 5, 2019 431
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Figure 2. Ablation of Fh1 in a Cells Recapitulates the Effects of Diabetes on Glucagon Secretion
(A) IHC for 2SC (green), glucagon (red) and overlay (yellow) islets from CTL (above) and Fh1aKOmice. Note strong 2SC labeling of most glucagon-positive cells.
Scale bar, 50 mm. Data are representative of four mice of each genotype.
(B) Glucagon secretion in CTL and Fh1aKO islets measured during 1 hr static incubations at 1 and 6mMglucose. *p < 0.05 versus 1mMglucose; #p < 0.05 versus
corresponding group in CTLmice (n = 7–8 experiments using islets from three CTL and three Fh1aKOmice). Inset: glucagon secretion at 1 and 6mMglucose after
compensating for a cells that retain Fh1.
(C) Glucagon content in islets from CTL and Fh1aKO mice. *p < 0.05 (n = 3 mice for each genotype). Inset: glucagon content after compensating for a cells that
retain Fh1.
(D) Electron micrographs of a cells in a CTL islet (left), a normal a cell in an Fh1aKO islet (center) and an abnormal a cell in an Fh1aKO islet (right; n = 5 cells). Scale
bar, 2 mm.
All data presented as mean values ± SEM of indicated number of experiments. See also Figure S2.but stimulated glucagon secretion (Figure 1F), echoing the
changes seen in Fh1bKO mice (Figure S1D). Collectively, these
data suggest that ablation of Fh1 in b cells also increases intra-
cellular fumarate levels in a cells by a systemic effect and this
underlies the observed dysregulation of glucagon secretion.
Ablation of Fh1 in a Cells Mimics the Effects of
Hyperglycemia on Glucagon Secretion
We generated a cell-specific Fh1 knockout (Fh1aKO) mice to
explore the role of reduced fumarase activity and consequent
increased fumarate in the dysregulation of glucagon secretion.
Deletion of fumarase, inferred from 2SC labeling, occurred in
58% ± 18%of a cells (n = 4mice; Figure 2A). Glucagon secretion
in Fh1aKO islets at 1 mM glucose was reduced by >40%, and
elevating glucose to 6mMwas, unlike the response of CTL islets,
not associated with a statistically significant suppression at
elevated glucose in Fh1aKO islets (Figure 2B). These changes
were associated with a 50% reduction in islet glucagon content
(Figure 2C).We corrected (mathematically) glucagon secretion in
Fh1aKOmice, to account for the 42% of a cells in which recom-
bination did not occur, by assuming that glucagon secretion by
a cells in this model was the same as in CTL islets. This analysis
suggests that, in Fh1aKO, the residual glucagon secretion is
limited to only z15% of that in CTL islets and that increasing432 Cell Metabolism 29, 430–442, February 5, 2019glucose from1 to 6mMstimulated rather than inhibited glucagon
secretion (Figure 2B, inset). Analogously, we estimate that
glucagon content in the Fh1aKO mice is reduced by 90%: the
40% of a cells in which recombination did not occur will account
for 650 pg/islet (1,629 3 0.4) of the 830 pg/islet in the Fh1aKO.
Thus, 180 pg/islet is what can be accounted for by the fraction
of a cells that have lost Fh1 (Figure 2C, inset).
In Fh1aKOmice, insulin secretion and content are normal (Fig-
ures S2A and S2B) and they exhibit lower plasma glucose levels
than CTLs during an intraperitoneal glucose tolerance test
(Figure S2C). Insulin tolerance tests did not suggest increased in-
sulin sensitivity that could account for the improved glucose
tolerance in Fh1aKO mice (Figure S2D).
Electron microscopy revealed that a subset of a cells in
Fh1aKO islets exhibit abnormal ultrastructural morphology,
including swollen mitochondria and fewer secretory granules,
while others have normal mitochondria comparable with CTL
islets (Figure 2D).
Defective Glucose Regulation of Glucagon Secretion in
Hyperglycemic Mice Results from Increased KATP
Channel Activity
We hypothesized that the dysregulation of glucagon secretion
in the Fh1bKO mice is a consequence of hyperglycemia. If this
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Figure 3. Hyperglycemia-Induced Changes in
Glucagon Secretion Are Corrected by Modu-
lation of KATP Channels
(A) IHC for succination (2SC) in CTL and bV59M
islets. Scale bar, 50 mm.
(B and C) Glucagon secretion in hyperglycemic
Fh1bKO (B) and bV59M (C) islets measured during
1 hr static incubations at 1 and 6 mM glucose in the
absence or presence of a low concentration (10 mM)
of the KATP channel blocker tolbutamide. *p < 0.05
versus 1 mM glucose (n = 7–8 experiments using
islets from at least three Fh1bKO and three bV59M
mice).
(D) As in (B) and (C), but experiments obtained from
CTL littermates of (n = 6 experiments/6 mice)
Fh1bKO and bV59M mice (n = 6–12 experiments/6
mice). *p < 0.05 versus 1 mM glucose, #p < 0.05
versus 1 mM glucose without tolbutamide.
(E) [Ca2+]i measurements in a cells, using the calcium
dye fluo4, within CTL (black) or hyperglycemic
Fh1bKO (red) islets at 1 and 20 mM glucose as
indicated. In both genotypes a cells were identified
by the [Ca2+]i response to adrenaline.
(F) Histogram summarizing effects of increasing
glucose on [Ca2+]i, measured using fluo4, in a cells
from normoglycemic CTL (black) and hyperglycemic
Fh1bKO (red) islets as indicated. Data are presented
as area under the curve. *p < 0.05 versus 1 mM
glucose in CTL mice. #p < 0.05 versus 1 mM glucose
in Fh1bKO mice. Data are from indicated number of
cells (n) in three islets from one CTL mouse and five
islets from two Fh1bKO mice, respectively.
All data presented as mean values ± SEM of indi-
cated number of experiments. See also Figure S7.is the case, glucagon secretion defects similar to those observed
in Fh1bKO mice should also develop in other models of hy-
perglycemia. We tested this using an inducible mouse model
of neonatal diabetes with b cell-specific expression of an
activating KATP channel mutation (Kir6.2-V59M) (bV59M) (Brere-
ton et al., 2014). Nutrient-stimulated insulin secretion was
switched off in bV59M mice at 12–14 weeks of age. After
14 days of hyperglycemia, a cells in bV59M islets showed similar
levels of protein succination as a cells in islets from hyperglyce-
mic FH1bKO mice (compare Figures 1C and 3A; see also
Figure 6).
Similar to Fh1bKO mice, glucagon secretion in bV59M islets
showed abnormal glucose regulation: glucagon secretion at
1 mM glucose was low and stimulated rather than inhibitedCell Meby 6 mM glucose. In both Fh1bKO and
bV59M islets, normal glucose regulation
of glucagon secretion was restored in
the presence of 10 mM tolbutamide, a
blocker of ATP-sensitive K+ (KATP) chan-
nels (Figures 3B and 3C). This concen-
tration will block approximately 50% of
KATP channel activity (Trube et al., 1986).
In islets from normoglycemic CTL mice,
application of 10 mM tolbutamide lowers
glucagon secretion at 1 mM glucose by
40% and elevation of glucose no longer
produces a statistically significant reduction of glucagon secre-
tion (Figure 3D).
These data suggest that the glucagon secretion defect in
hyperglycemic bV59M and Fh1bKO mice results from a small
increase in KATP channel activity; if the increase was dramatic,
then the low concentration of tolbutamide used would not be
able to modulate glucagon secretion. The effects of tolbutamide
are not mediated by stimulation of insulin secretion and there
were no statistically significant effects of tolbutamide on insulin
secretion in Fh1bKO islets (Figure S1E). If KATP channel activity
is increased in a cells from hyperglycemic Fh1bKO mice, then
electrical activity should be reduced, similar to what is produced
by pharmacological (using diazoxide) or genetic activation (by
expression of the V59M gain-of-function mutation) (Zhangtabolism 29, 430–442, February 5, 2019 433
et al., 2013). Direct electrophysiological measurements are diffi-
cult in diabetic Fh1bKO mice and recordings of the ATP/ADP
ratio require prior infection and culture of the islets. Therefore,
we used a cell intracellular calcium ([Ca2+]i) measurements as
a proxy for electrical activity (and the cytoplasmic ATP/ADP
ratio). We identified a cells in islets from CTL and Fh1bKO mice
by the spontaneous [Ca2+]i oscillations at 1 mM glucose and
responsiveness to adrenaline (Hamilton et al., 2018). In the CTL
a cells, [Ca2+]i was only marginally reduced by increasing
glucose from 1 to 20mM (Figure 3E), but this effect did not reach
statistical significance (Figure 3F). When the same type of mea-
surements were repeated in hyperglycemic Fh1bKO mice,
[Ca2+]i was reduced by 60% and increased by 150% in response
to an elevation of glucose to 20 mM (Figures 3E and 3F). Collec-
tively, these observations suggest that the cytoplasmic ATP/
ADP ratio is reduced in a cells from hyperglycemic Fh1bkO
mice, leading to the increase in KATP channel activity that
accounts for the inverted response to glucose.
Hyperglycemia Results in Intracellular Acidification of
a Cells
The finding that KATP channel closure could correct the dysregu-
lated glucagon secretion in hyperglycemic bV59M and Fh1bKO
mice suggests that ATP production in the a cell was compro-
mised. Because succination was observed in a cells in both
mouse models, we speculated that the reduced ATP production
could be linked to increased fumarate caused by a reduction in
fumarase expression. However, fumarase was detectable by
immunocytochemistry in a cells of Fh1bKO mice (Figure S2E).
Thus, reduced expression of Fh1 is unlikely to explain the
glucagon secretion defect and the protein succination in a cells
from Fh1bKO mice.
The mitochondrial matrix is alkaline, and Krebs cycle enzymes
typically have their maximum catalytic activity at high pH (Bern-
stein and Everse, 1978; Lai and Cooper, 1986; Willson and
Tipton, 1980).We confirmed that this was also the case for fuma-
rase: there was a strong reduction of fumarase activity when pH
lowered from 7.6 to 7 and 6.6 in a cell-free system (Figure S2F).
At the lowest pH, fumarase activity was only 5% of that seen at
pH 7.6. Therefore, we conclude that the reduced fumarase activ-
ity in a cells may be a consequence of intracellular acidification
rather than lowered gene expression.
b cells from Fh1bKO mice have a lower cytoplasmic pH (pHi),
an effect that was attributed to the accumulation of acidic fuma-
rate (Adam et al., 2017), and pHi is also lower in a cells from
hyperglycemic Fh1bKO mice than in CTLs (Figure 4A). Although
increasing glucose to 20 mM reduced pHi in a cells in islets from
both CTL and normoglycemic Fh1bKO mice, no acidification
was seen in a cells from hyperglycemic Fh1bKO mice (Figures
4B and 4C).
Intracellular Acidification Results from SGLT-
Dependent Intracellular Na+ Accumulation
Intracellular pH is controlled by plasmalemmal and intracellular
Na+-H+ exchangers (NHEs) (Casey et al., 2010). The significance
of NHEs in the regulation of a cell pHi is illustrated by the prompt
reduction of pHi observed when extracellular Na
+ is reduced
from the normal 140 mM to 10 mM (Figures S3A and S3B). Of
the NHEs, NHE1 (SLC9A1) and NHE6 (SLC9A6) are expressed434 Cell Metabolism 29, 430–442, February 5, 2019at particularly high levels in mouse and human a cells (Blodgett
et al., 2015; DiGruccio et al., 2016). We used ethylisopropyl
amiloride (EIPA), an inhibitor of plasmalemmal NHEs (Masereel
et al., 2003), to explore the role of NHEs in control a cells where
pHi and normal ionic gradients are maintained. In wild-type
islets exposed to 10 mM glucose, EIPA produced a concentra-
tion-dependent intracellular acidification in a cells (Figures 4D
and 4E).
Glucose uptake in a cells is partially mediated by SGLTs (Bon-
ner et al., 2015). We therefore speculated that hyperglycemia
may cause intracellular acidification via an increase in the intra-
cellular Na+ concentration ([Na+]i).
Although islets express both SGLT1 (encoded by Slc5a1) and
SGLT2 (Slc5a2), SGLT1 is expressed at much higher levels than
SGLT2 but still only at 1% of levels found in the kidney (Fig-
ure S3C). In mouse a cells, SGLT1 (Slc5a1) is expressed at
very low levels (1%) compared with GLUT1 (Slc2a1) and
GLUT3 (Slc2a3) (DiGruccio et al., 2016), and their contribution
to glucose uptake is therefore likely to be negligible. Despite
the low expression in mouse a cells, the SGLTs nevertheless
result in glucose-dependent Na+ uptake. We demonstrated
this using the non-metabolized SGLT substrate a-methyl-D-
glucopyranoside (aMDG) (Wright et al., 2011). As shown in Fig-
ures 4F and 4G, application of aMDG increased [Na+]i in a cells
and this effect was almost fully prevented by the SGLT inhibitor
phlorizin (Wright et al., 2011).
SGLT-Mediated Na+ Uptake Leads to Intracellular
Acidification and Reduced ATP Production in the
Hyperglycemic a Cell
We established a tissue culture protocol to test the effects of
high glucose and Na+ uptake on a cell function. Briefly, isolated
wild-type islets were cultured for 48 hr at 5, 11–12 (11), or
20 mM glucose (Figure 5A). We found that culturing islets at
11 mM glucose was optimal for both glucose-regulated
glucagon and insulin secretion. Thus, we used 11 mM glucose
as the ‘‘normoglycemic’’ CTL. This glucose concentration is in
fact close to the fed plasma glucose levels in CTL mice (Figures
S1A and S1B; see also https://phenome.jax.org/measures/
32301) and similar to that found in Fh1bKOmice before hypergly-
cemia and the defects of glucagon secretion developed (Figures
1A, S1A, and S1B).
We confirmed that culture in high glucose (20 mM) for 24 hr re-
sulted in 2SC staining of peripheral islet cells that was not
observedwhen isletswereculturedat 5mMglucose (FigureS4A).
Culture for 48 hr at 20mMglucose led to intracellular acidifica-
tion of a cells compared with a cells in islets cultured at 11 mM
glucose. Quantitatively, this effect was similar to the acidification
observed in a cells in acutely isolated islets from hyperglycemic
Fh1bKO mice compared with normoglycemic CTLs (compare
Figures 4A and 5B). Importantly, the effect of high glucose cul-
ture was almost fully prevented when the SGLT inhibitor phlorizin
was included in the culture medium (Figure 5B). ‘‘Hyperglyce-
mia’’ in vitro did not result in acidification of the b cells but rather
increased pHi in these cells. This effect was not affected by
phlorizin (Figure S5A), suggesting that different mechanisms
control pHi in a and b cells.
We investigated the impact of high glucose culture on the cyto-
plasmic ATP/ADP ratio (ATP/ADPc). A glucose-induced increase
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Figure 4. Hyperglycemia Results in Intracel-
lular Acidification of a Cells
(A) Histogram summarizing basal a cell intracellular
pH (pHi) measured using the pH indicator semi-
naphthorhodafluor (SNARF) in a cells in islets from
CTL (black) and hyperglycemic Fh1bKO (red) mice.
Number of cells indicated below the respective bars
in the histogram. *p < 0.05 versus CTL.
(B) pHi measured in a cells in islets from CTL (black)
and hyperglycemic Fh1bKO (red) mice at 3 mM and
20 mM glucose. The traces have been offset to
reflect the true difference in fluorescence ratios
(F650/550) between CTL and Fh1bKO a cells. Mea-
surements were performed in acutely isolated intact
islets.
(C) Net effect of 20 mM glucose on pHi (DF650/550)
in a cells from CTL (black) and nearly normoglycemic
(gray) or hyperglycemic (red) Fh1bkO mice. Number
of cells (n) indicated above the respective bars in the
histogram. *p < 0.05 versus CTL; #p < 0.05 versus
basal (at 3 mM glucose).
(D) Dose-dependent acidification of wild-type a cells
in response to ethyl-isopropyl amiloride (EIPA)
measured using the pH indicator SNARF.
(E) Histogram summarizing the effect of EIPA on a
cell pHi in wild-type islets. Number of cells indicated
above the respective bars in the histogram. *p < 0.05
versus basal (no EIPA).
(F) Effect of the non-metabolizable glucose
analogue a-methyl-D-glucopyranoside (aMDG) on
cytoplasmic Na+ ([Na+]i) in wild-type a cells in the
absence (black) and the presence (red) of phlorizin.
Glucose (1 mM) was present throughout. [Na+]i was
measured using Sodium Green. Fluorescence (F)
values have been normalized to that at 1 mM
glucose (F0).
(G) Effect of aMDG on [Na+]i in the absence (black)
and presence (red) of phlorizin in wild-type islets, as
indicated. Data in (A) and (B) normalized to Sodium
Green fluorescence under basal conditions (1 mM
glucose; n = 59 cells) *p < 0.05 versus 1 mM
glucose; #p < 0.05 versus aMDG in the absence of
phlorizin.
Data are presented as mean values ±SEM of indi-
cated number of experiments (n). In (B), (D), and (F),
representative single-cell traces have been selected
for display. See also Figures S2 and S3.inATP/ADPcunderlies the reductionofacell KATP channel activity
proposed to culminate in inhibition of glucagon secretion (see
schematic in Figure S7). This would account for the reduced
a cell [Ca2+]i oscillatory activity in hyperglycemic Fh1bKO mice
and the stimulation by high glucose/tolbutamide. In islets
cultured at 11 mM glucose, raising the glucose concentration
from 1 to 20 mM (after a pre-incubation period of 20 min at
1 mM glucose) led to an increase in ATP/ADPc (Figures 5C and
5D). However, in islets cultured at 20 mM glucose, acutely
elevating glucose from 1 to 20 mM produced a much smaller in-
crease in ATP/ADPc. This effect of hyperglycemia was prevented
in the presence of phlorizin and glucose remained capable of
increasing ATP/ADPc even when islets were cultured at 20 mM
glucose with phlorizin.
Finally, we examined the impact of high glucose culture and
intracellular acidification on glucagon secretion. Islets culturedat 12 mM glucose responded to an elevation of glucose from
1 to 20 mM glucose with inhibition of glucagon secretion (Fig-
ure 5E). However, following culture of islets at 20 mM glucose,
glucagon secretion measured at 1 mM glucose was reduced
by 50% compared with that seen in islets cultured at 12 mM
glucose. Furthermore, increasing the glucose concentration
stimulated rather than inhibited glucagon secretion (echoing
what is observed in Fh1bKO islets from hyperglycemicmice; Fig-
ure S1D). Both these effects of high glucose culture were
reversed by phlorizin. In contrast, the SGLT2 inhibitor dapagliflo-
zin did not restore normal glucose regulation in high glucose-
cultured islets (not shown), in agreement with the low expression
of Slc5a2 in mouse islets (Figure S3C).
The effects of high glucose incubation were also studied in hu-
man islets following culture at 5 or 20 mM glucose for 24 hr.
Although islets cultured at 5 mM (normoglycemia in humans)Cell Metabolism 29, 430–442, February 5, 2019 435
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Figure 5. SGLT-Mediated Na+ Uptake Leads to Intracellular Acidification and Reduced ATP Production in the Hyperglycemic a Cell
(A) Schematic of ex vivo experiments. Islets are isolated from mouse pancreas and incubated in 11–12 or 20 mM glucose for 48 hr. These concentrations
approximate to fed plasma glucose levels before and after hyperglycemia develops in Fh1bKO mice (see Figures S1A and S1B). Figure was made using Servier
medical ART.
(B) Histogram summarizing basal pHi measured using the pH indicator SNARF in a cells from wild-type islets incubated for 48 hr at 11 mM or 20 mM glucose, or
20 mM glucose plus 50 mM phlorizin. Number of cells (n) indicated below the respective bars in the histogram; *p < 0.05 versus 11 mM glucose. #p < 0.05 versus
20 mM glucose.
(C) Cytoplasmic ATP/ADP ratio at 1 and 20 mM glucose (indicated above recording) in a cells from wild-type islets cultured for 48 hr at 11 mM or 20 mM glucose,
or 20 mM glucose plus 50 mM phlorizin.
(D) Histogram summarizing the net effect of glucose on the cytoplasmic ATP/ADP ratio (DATP/ADPc) in a cells from wild-type islets cultured at 11 or 20 mM
glucose in the absence or presence of 50 mM phlorizin as indicated. *p < 0.05 versus 1 mM glucose; #p < 0.05 versus 20 mM glucose in islets cultured at 11 mM
glucose.
(E) Glucagon secretion measured at 1 or 20 mM glucose in wild-type islets cultured for 48 hr at 12 mM, 20 mM glucose, or 20 mM glucose plus 50 mMphlorizin as
indicated. *p < 0.05 versus 1mMglucose in respective group; #p < 0.05 versus 20mMglucose in islets cultured at 20mMglucose in the absence of phlorizin (n = 8
experiments using islets from six mice).
(F) As in (E) using wild-type islets that were cultured for 48 hr at 12 mM glucose alone (white bars) or in the presence of 10 mMNHE inhibitor EIPA (gray bars) in the
absence or presence of 10 mM tolbutamide as indicated. *p < 0.05 versus 1 mM glucose in respective group; #p < 0.05 versus 20 mM glucose in islets cultured in
the absence of EIPA; #p < 0.05 versus 1 mM glucose EIPA-incubated islets in the absence of tolbutamide (n = 3–8 experiments using islets from five mice).
Data are presented as mean values ±SEM of indicated number of experiments (n). Traces in (C) represent average response in all cells. See also Figure S4.
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Figure 6. Protein Succination Persists after Restoration of Normoglycemia
(A) Glucagon secretion at 1 and 20 mM glucose in acutely isolated islets from CTL and hyperglycemic Fh1bKO mice. *p < 0.05 versus 1 mM glucose (n = 9
experiments using islets from four mice of each genotype).
(B) As in (A) but after 72 hr of culture at 12 mM glucose. *p < 0.05 versus 1 mM glucose (n = 9 experiments for each genotype using islets from four CTL and four
Fh1bKO mice).
(legend continued on next page)
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responded to high glucose with 40%–60% suppression of
glucagon secretion, no suppression of glucagon secretion by
elevated glucose was detected in islets cultured at 20 mM
glucose (Figure S4B).
In mouse islets cultured at 20 mM glucose for 48 hr, insulin
secretion subsequently measured at 1 mM glucose was not
affected, but the response to 20 mM glucose increased by
>700% compared with islets cultured at 12 mM glucose (Fig-
ure S5B). Phlorizin did not affect insulin secretion (echoing the
lack of effects on pHi), and it is consequently unlikely that the ef-
fects on glucagon secretion are secondary to changes of insulin
secretion.
The capacity of phlorizin to counteract the adverse effects of
chronic exposure to high glucose on glucagon secretion was
not simply due to inhibition of a cell electrical activity: in a cells
exposed to 20mM glucose, there was no effect on the interspike
membrane potential, the peak potential of the action potential,
and action potential frequency (Figures S4C and S4D).
We considered whether intracellular acidification is enough to
cause dysregulation of glucagon secretion. We incubated islets
for 48 hr at 12 mM glucose in the absence or presence of the
NHE inhibitor EIPA (10 mM). Although islets cultured at 12 mM
glucose alone responded to a subsequent increase in glucose
from 1 to 20 mM with inhibition of glucagon secretion, islets
cultured in the presence of EIPA exhibited an inverted response
and elevation of glucose stimulated glucagon secretion (Fig-
ure 5F), echoing what is seen in Fh1bKO islets and in wild-type
islets after high glucose culture (Figures S1D and 5E, respec-
tively). We examined whether this might be due to increased
KATP channel activity. Indeed, treatment of islets with 10 mM
tolbutamide increased glucagon secretion at 1 mM and restored
normal glucose regulation of glucagon secretion by high glucose
in EIPA-treated islets (Figure 5F). Effects similar to those pro-
duced by EIPA on glucagon secretion were obtained during
long-term exposure to D-glyceraldehyde (Figure S4F), which
also produces intracellular acidification (Figures S4D and S4E).
Reduction in Hyperglycemia Rescues Glucagon
Secretion, but Not Succination
If the dysregulation of glucagon secretion in diabetic Fh1bKO is
caused by hyperglycemia, then it should be possible to reverse
the secretion defect simply by culturing the islets at normal
glucose. Glucagon secretion in acutely isolated islets from hy-
perglycemic Fh1bKO mice was only 40% of that in CTL islets
and was unaffected by glucose, unlike what was seen in CTL is-
lets (Figure 6A). Culture alone reduced glucagon secretion in CTL
islets by >70% compared with acutely isolated islets, but resid-
ual glucagon secretion remained inhibited when glucose was
increased from 1 to 20mM (Figure 6B). There was a tendency to-
ward restoration of normal glucose regulation when Fh1bKO is-
lets from hyperglycemic mice were cultured at 12 mM glucose(C) Glucagon content in CTL and Fh1bKO islets either acutely isolated or after 72
(D) Immunofluorescence for 2SC (green), glucagon (red), insulin (blue), and overlay
bV59M mice (treated with glibenclamide). Note strong 2SC labeling of most gluc
(E) IHC for succination (2SC) in islets from non-diabetic (CTL) individuals and pa
(F) Immunofluorescence for 2SC (green), glucagon (red), DAPI (blue), and overlay
most glucagon-positive cells. Scale bar, 50 mm. Data in (E) and (F) are represent
Data are presented as mean values ± SEM of indicated number of experiments
438 Cell Metabolism 29, 430–442, February 5, 2019for 72 hr (Figure 6B). Islets from Fh1bKO mice contain 200%
more glucagon than non-diabetic CTLs, a difference that was
only partially reversed after culturing the islets at 12 mM glucose
(Figure 6C).
The dysregulation of glucagon secretion in bV59M mice is
associated with strong 2SC labeling of the a cell (Figure 3A).
We used this mousemodel to test the reversibility of protein suc-
cination (i.e., without genetic deletion of Fh1 and strong 2SC
labeling of the b cells). In normoglycemic bV59M mice (i.e.,
before tamoxifen treatment), no succination was seen in islet
cells (Brereton et al., 2014). Following transgene induction and
14 days of hyperglycemia, stronger 2SC staining was observed
in the a cells than b cells. Normoglycemia was then restored
by treatment with glibenclamide. However, even after 2 weeks
of glibenclamide treatment, the a cells remained 2SC positive
(Figure 6D).
Persistent 2SC labeling of peripheral cells (likely to be a cells)
was also seen in islets from diabetic GK rats 10 days after
plasma glucose levels had been normalized by bariatric (Roux-
en-Y gastric bypass [RYGB]) surgery (Ramracheya et al.,
2016); no 2SC labeling was observed in normoglycemic control
(Wistar) rats (Figure S6A). Despite the normalization of plasma
glucose, glucagon secretion at 1 mM glucose remained low in
RYGB rats and 6 mM glucose was without a statistically signifi-
cant inhibitory effect (Figure S6B).
Protein succination (2SC staining) was also seen in postmor-
tem specimens of islets/pancreases from T2D patients and
absent in islets from non-diabetic individuals (Figure 6E). In hu-
man T2D pancreatic islets (Table S1), 2SC staining appeared
to be most prominent in a cells (Figure 6F).
Protein Succination Is Observed in Cardiomyocytes and
Renal Tubular Cells from Hyperglycemic Fh1bKO Mice
Evidence for protein succination (2SC staining) was also
observed in cardiomyocytes (Figure 7A) and renal tubular cells
(Figure 7B) in hyperglycemic Fh1bKO mice, but not in non-dia-
betic littermate CTLs or young Fh1bKO mice. However, 2SC
staining was scattered, suggesting that fumarate levels were
only elevated in some cells.
2SC labeling of a cells and renal tubular cells was not reversed
by administration of phlorizin in vivo (400 mg/kg subcutaneously)
to hyperglycemic Fh1bKO mice (plasma glucose: >20 mM) for
7 days (data not shown). This is consistent with the persistence
of 2SC labeling in the GK rats and bV59Mmice following normal-
ization of plasma glucose.
DISCUSSION
We demonstrate that chronic hyperglycemia results in changes
in glucagon secretion similar to those that occur in diabetes.
These changes, which occur in three hyperglycemic rodenthr of culture. *p < 0.05 versus CTL.
(yellow) islets from CTL, hyperglycemic bV59M (diabetic), and normoglycemic
agon-positive cells. Scale bar, 50 mm.
tients with type-2 diabetes (T2D). Scale bar, 50 mm.
(yellow) in islets from patients diagnosed with T2D. Note strong 2SC labeling of
ative of six donors for both the non-diabetic (CTL) and T2D groups.
(n). See Table S1 for details on the donors.
AB
C
Figure 7. Protein Succination in Renal
Tubular Cells and Cardiomyocytes from
Hyperglycemic Fh1bKO Mice
(A) IHC for 2SC in CTL (left) and diabetic Fh1bKO
(right) hearts showing staining in a subset of cells in
diabetic animals but not in the non-diabetic CTLs.
Scale bar, 50 mm.
(B) As in (A) but showing sections of kidney in CTL
(left) and normoglycemic (middle) or hyperglycemic
(right) Fh1bKO mice as indicated.
(C) Schematic of the proposed relationship between
hyperglycemia, impaired ATP production, and pro-
tein succination. The increased intracellular fuma-
rate resulting from reduced activity of fumarase
leads to protein succination. The sites of action of
SGLT inhibitors and tolbutamide are indicated.
Sections in (A) and (B) are representative of obser-
vations in >10 animals of both genotypes.models of diabetes, manifest as a reduction of glucagon secre-
tion at low glucose and stimulation, rather than inhibition, in
response to high glucose. Similar disturbances are induced after
culture of mouse and human islets under hyperglycemic condi-
tions (20 mM glucose for 24–48 hr). Our findings are broadly
consistent with the report that chronic glucose infusion in rats
leads to moderate hyperglycemia (15 mM) and hyperglucago-
nemia, despite stimulation of insulin secretion (Jamison
et al., 2011).
Intracellular Acidification Links Hyperglycemia to
Impaired ATP Production
We propose a model that explains the dysregulation of glucagon
secretion induced by hyperglycemia (Figure 7C). In this model,
hyperglycemia results in increased Na+ uptake mediated by
plasmalemmal SGLTs and a consequential increase in [Na+]i.
The transmembrane Na+ gradient normally drives the uphill
(i.e., against an electrochemical gradient) transport of several
molecules in the cell, including H+. An increase in [Na+]i will there-
fore interfere with the removal of H+ from the cytoplasm. This will
cause intracellular acidification (i.e., an increased intracellular H+
concentration).
The critical role played by intracellular acidification as the
causal factor leading to dysregulation of glucagon secretion isCell Meunderscored by the effects of EIPA. Addi-
tion of this NHE inhibitor leads to acidif-
ication and long-term treatment results in
inverted glucose regulation of glucagon
secretion (i.e., stimulation rather than inhi-
bition) that can be corrected by low con-
centrations of tolbutamide.
In astrocytes, mild cytoplasmic acidifica-
tion results in amarked reductionof intrami-
tochondrial (matrix) pH (pHm) and inhibition
of oxidative metabolism (Azarias et al.,
2011). By analogy, we propose that the
reductionof pHi andpHm inducedbyhyper-
glycemia will reduce the activity of both the
cytoplasmic and mitochondrial forms of
fumarase in a cells, accounting for theincreased 2SC labeling. Because fumarate is an acid, reduced
fumarase activity (via accumulation of fumarate) will result in
further acidification, thus establishing a vicious cycle of pro-
gressive intracellular acidification. Fumarate can leave the mito-
chondria and be processed in the cytosol, as shown by the
observation that the cytoplasmic form of fumarase (lacking the
mitochondrial leading sequence) when re-introduced into Fh1-
deficient cells ‘‘rescues’’ many of the consequences of deletion
of Fh1 (Adam et al., 2013, 2017; Ternette et al., 2013). We spec-
ulate that reverse operation of this mechanism could result in
transport of cytoplasmic fumarate into the mitochondria and
thus contribute to matrix acidification.
Themetabolicconsequencesof reduced fumaraseactivitymay
be exacerbated by the effects of fumarate on other metabolic
enzymes. For example, fumarate reduces the activity of other
enzymes integral to both glycolysis and the TCA cycle, including
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and aco-
nitase (Blatnik et al., 2008; Ternette et al., 2013).
An alkaline pHm is required for ATP production, which is ener-
gized by the downhill movement of H+ in an electrochemical
gradient across the inner mitochondrial membrane. In b cells,
alkalinization of the mitochondrial matrix has been shown to
correlate with mitochondrial ATP production (Akhmedov et al.,
2010). When the mitochondrial matrix has undergone sufficienttabolism 29, 430–442, February 5, 2019 439
acidification, H+ flux through ATP synthase becomes sufficiently
reduced to impair ATP production.
The resultant fall in the ATP/ADP ratio results in increased KATP
channel activity. Closure of the KATP channels is required for
normal glucose regulation of glucagon secretion. This model ex-
plains why the effects of chronic hyperglycemia and inhibition of
NHEs resemble those produced by inhibition of mitochondrial
ATP synthesis by oligomycin or pharmacological activation of
the KATP channels by diazoxide (Zhang et al., 2013). We found
that a low concentration of the KATP channel inhibitor tolbuta-
mide increased glucagon secretion at 1 mM glucose and
restored normal glucose regulation (inhibition by high glucose)
in islets from hyperglycemic Fh1bKO and bV5M mice, whereas
it reduced glucagon secretion at low glucose in CTL mice. These
observations are consistent with a bell-shaped relationship be-
tween KATP channel activity and glucagon secretion (see legend
to Figure S7) and is also supported by our observation of
reduced [Ca2+]i oscillatory activity in a cells from diabetic
Fh1bKO mice (Figures 3F and 3G).
Phlorizin also restores glucose-regulated glucagon secre-
tion, but its mode of action is completely different to that of
tolbutamide. Although tolbutamide corrects the ‘‘symptoms’’
of the defect, phlorizin corrects the cause. By inhibition of
SGLT activity, phlorizin prevents Na+ uptake and intracellular
acidification with resultant preservation of mitochondrial ATP
production.
Changes in Glucagon Content with Hyperglycemia and
Loss of FH
Although the effects on glucagon secretion of deleting Fh1 in
a and b cells are similar, the effects on glucagon content are
not. Thus, although glucagon content is increased in Fh1bKO
islets, it is decreased in Fh1aKO islets. The reduction of
glucagon content in the Fh1aKO mice might be explained by
the activation of cataplerosis to replenish the Krebs cycle inter-
mediates following the complete genetic deletion of fumarase.
Deamination of the amino acids that would otherwise be used
for glucagon biosynthesis represents an obvious source, similar
to the explanation for the >95% reduction of insulin content in
b cells from Fh1bKO mice (Adam et al., 2017). The strong
reduction of glucagon content (90%) is probably a major fac-
tor explaining the 90% decrease in glucagon secretion in
Fh1aKO islets. Importantly, in Fh1aKO islets, glucose tends to
stimulate rather than inhibit glucagon secretion, echoing what
is seen in the presence of the membrane-permeable exogenous
dimethyl fumarate and in islets isolated from hyperglycemic
mice. It is unclear precisely why glucagon content is increased
in hyperglycemic Fh1bKO islets and in islets from human T2D
donors. The simplest explanation is that the rate of secretion
is reduced by 70%. Although fumarase activity is reduced suf-
ficiently to result in 2SC staining, the a cells in the hyperglyce-
mic models may nevertheless retain sufficient enzyme activity
not to deplete the amino acid pool needed for glucagon
biosynthesis.
Functional Significance of Protein Succination
It is interesting that a cells in islets from patients with T2D
showed strong protein succination. We also observed particu-
larly strong 2SC labeling of a cells in diabetic bV59M mice,440 Cell Metabolism 29, 430–442, February 5, 2019whereas staining of the b cells was much weaker. Thus, the
impact of hyperglycemia in a and b cells must be quite different
and it is interesting that chronic hyperglycemia has opposite
effects in a (acidification) and b cells (alkalinization). Moreover,
phlorizin corrected the dysregulation of glucagon secretion
resulting from chronic hyperglycemia but did not affect the
hypersecretion of insulin.
We also found that protein succination was poorly reversible;
even after 2 weeks of glibenclamide treatment and normoglyce-
mia, a cells in bV59M showed protein succination. In this context
it is worth remembering that protein succination is an irreversible
chemical reaction. Thus, the lifespan of the succinated proteins
must exceed 2 weeks. It is also possible that succination inter-
feres with protein degradation and/or that hyperglycemia results
in permanent dysregulation of metabolism as a consequence of
hyperglycemic stress. The identity of all the succinated proteins
remains unknown, but immunohistochemistry suggests it is
extranuclear. Previous analyses of mouse and human islets indi-
cate that mitochondrial proteins like DJ-1 (a cellular anti-oxidant
response regulator) (Eberhard and Lammert, 2017; Jain et al.,
2012) become succinated in hyperglycemic Fh1bKO islets and
in diabetic human islets (Adam et al., 2017). The slow revers-
ibility of succination may also explain why restoration of normo-
glycemia (by culture or by RYGB surgery) is associated with only
partial recovery of normal glucose regulation of glucagon
secretion.
Protein Succination and Reduced Cardiac Mortality and
Renal Failure in Diabetic Patients Treated with SGLT2
Inhibitors
Interestingly, protein succination was also observed in renal cells
and cardiomyocytes, two cell types affected by secondary com-
plications of diabetes. This suggests that that the model can be
extended to other SGLT-expressing cells and that hyperglyce-
mia also leads to inhibition of fumarase in these cells. As in
a cells, reduced fumarase activity and intracellular acidification
can be expected to compromise ATP production and thereby
predispose to renal (Forbes, 2016) and cardiac failure (Brown
et al., 2016). This model is supported by the recent observation
that inhibition of SGLTs leads to reduced Na+ transport in the
heart (Bertero et al., 2018). We emphasize that there is no in-
crease in plasma fumarate levels in Fh1bKO mice. Thus, we
can exclude any possibility that export of fumarate from the
b cells may account for the 2SC labeling in the heart (which is un-
likely also from quantitative considerations).
We emphasize that protein succination should be regarded as
a biomarker of impaired mitochondrial metabolism rather than
the cause. Given that both heart and kidneys express SGLT2
(although at 10-fold higher levels in kidneys), this model may
give some insight into the dramatic reduction in cardiac mortality
and kidney disease observed in diabetic patients treated with
SGLT2 inhibitors (Wanner et al., 2016; Zinman et al., 2015).
Explanations to date have focused on altered intermediarymeta-
bolism (Ferrannini, 2017; Lopaschuk and Verma, 2016). The
‘‘Na+ toxicity’’ hypothesis outlined here not only provides an
alternativemode of action but also suggests a unifyingmolecular
mechanism underlying the spectrum of diabetes-associated co-
morbidities. The hypothesis we propose posits that tissues that
express SGLTs will be particularly sensitive to hyperglycemia.
Limitations of Study
The concepts presented in these studies are based on animal
experiments and it is now important to extend the model to hu-
man islets (and especially those from diabetic patients). Ulti-
mately, it will also be important to translate these observations
into improved therapy for diabetic patients. This will involve the
demonstration that normal counter-regulatory glucagon secre-
tion can be restored in diabetic patients by treatment with
SGLT inhibitors or low-dose sulfonylurea. In addition, we
acknowledge that, although protein succination, similar to that
found in a cells, is also observed in renal tubular cells and cardiac
myocytes, the upstream molecular mechanism leading to
reduced fumarase activity in these cells may be distinct from
that in a cells.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal Models: Mice
All animal experiments were conducted in accordance with the UK Animals Scientific Procedures Act (1986) and University of Oxford
local ethical guidelines. Animals were kept on a 12 hr light: dark cycle, at 22C. The mice used were either Fh1tm1Pjpfl/flRip2-Cre+/-
(designated Fh1bKO), whichwere generated originally by crossing Fh1tm1Pjpfl/fl (Pollard et al., 2007) with Tg(Ins2-Cre)23HerrCre recom-
binase, Rip2-Cre+/- (Herrera, 2000) (as described in Adam et al., 2017), or Fh1tm1Pjpfl/flGlu-iCre+/- (designated Fh1aKO), which
were generated by crossing Fh1tm1Pjpfl/fl (Pollard et al., 2007) with Glu-iCre+/- (Parker et al., 2012). Mice had been backcrossed on
a C57BL/6J background at least 5 times when the experiments commenced. Fh1 was deleted specifically in either b- or a-cells
respectively in these strains and littermates were used as controls.
Details of bKir6.2-V59M mice (that express a gain-of-function KATP channel mutation in the b-cells following tamoxifen induction)
are as described previously (Brereton et al., 2014). These mice were generated originally by crossing Kir6.2-V59M (Girard et al.,
2009) with mice expressing a tamoxifen inducible rat insulin promoter II (RIPII-Cre-ERT mice) (Dor et al., 2004). Mice were on
a mixed (C3H, C57BL/6, 129/sv) genetic background. Kir6.2-V59M expression was induced in pancreatic b-cells in mice at
12-14 weeks of age by a single subcutaneous injection of 0.4 ml of 20 mg/ ml tamoxifen in corn oil (Sigma). Littermates were
used as controls.
Some experiments were carried out with islets isolated from NMRI or C57BL/6J mice (referred to as wild-type) obtained from a
commercial supplier.
Animal Models: Rats
Experiments on rats were performed as described previously (Ramracheya et al., 2016). Briefly, adult maleWistar and Goto-Kakizaki
(TohiCskCrljCr) GK rats were used. TheGK rats were divided into either Roux-Y-gastric bypass procedure (RYGB) or sham-operation
groups.
Animals of both sexes were used for all islet experiments; neither have we observed nor has it been reported that there are sex
differences at the islet level. Therefore, we found it best to include both sexes, and in these studies we have not observed any
sex differences. We have previously reported, and discussed sex differences in the FH1bKO mouse model (Adam et al., 2017).
For all other in vivo experiments male mice were used.
METHOD DETAILS
Islet Isolation, Islet Culture and Hormone Secretion from Mouse Islets
Islets were isolated by collagenase or liberase digestion. After isolation, islets were transferred to RPMI-1640 supplemented with
5 mM glucose, 100 U/ml penicillin, 10 mg/ml streptomycin (P/S) and 10% fetal calf serum (FCS). In most experiments they were
kept in this medium at 37C in a humidified atmosphere (5% CO2/95% air) for <2 hr prior to experiments. However, in some exper-
iments, islets were cultured in RPMI-1640 (supplemented with 10%FCS and 1%P/S) containing either 5, 11-12 or 20mMglucose, or
20mMglucose to which was added either 50 mMof the SGLT inhibitor phlorizin (dissolved in DMSO; final concentration: 0.1% v/v), or
the NHE inhibitor ethylisopropyl amiloride (EIPA, dissolved in DMSO: 0.1% v/v) for 48 hr prior to the hormone release measurements
(as indicated). Dimethyl fumarate was dissolved in DMSO (0.1% v/v). Control experiments were performed in the presence of the
same concentration of DMSO.
In all cases, hormone secretion was measured from batches of 10-12 islets. Size-matched islets were hand-picked and washed
twice in glucose-free RPMI-1640 (supplemented with 100 U/ml penicillin, 10 mg/ml streptomycin and 10%FCS). They were pre-incu-
bated for 1 hr in a humidified chamber at 37C (5%CO2/95% air) in 300 ml of Krebs-Ringer buffer (KRB) which contained the following
(mM) 140 NaCl, 3.6 KCl, 2.6 CaCl2, 0.5 MgSO4.7H2O, 0.5 NaH2PO4, 2 NaHCO3, 5 HEPES and 2 mg/ml BSA (pH adjusted to 7.4 with
1 M NaOH) and 1 mM glucose. The pre-incubation buffer was discarded and the islets were stimulated for a further 1 h with the test
conditions indicated. An aliquot of the supernatant was collected and stored at -20C for quantification of either insulin or glucagon
secretion by radioimmunoassay. The remaining supernatant was discarded and the islets were lysed in 100 ml of ice-cold acid ethanol
solution (containing ethanol, H2O and HCl in a ratio of 52:17:1) to release their hormone content. Lysates were immediately frozen at
-20C for later analysis. Insulin (Millipore) and glucagon (Euro-diagnostica) was determined by commercial radio-immunoassays
following the manufacturer’s protocols.
Plasma Glucose Measurements
Fed blood glucose levels were determined with an Accuchek Aviva meter at approximately 9 am.
Plasma Fumarate Measurements
Fumarate was extracted from mouse plasma and analyzed as described previously (Spegel et al., 2013). Plasma fumarate concen-
trations were calibrated against an external standard of Na2-fumarate.e2 Cell Metabolism 29, 430–442.e1–e4, February 5, 2019
Glucose and Insulin Tolerance Test in Fh1aKO Mice
In the glucose tolerance tests, male Fh1aKOmice and control littermates were fasted for 6 hr from 8.30 am and fasting blood glucose
was measured, the mice were then injected intraperitoneally with 2 g/kg body weight of D-glucose in PBS and blood glucose levels
were measured 15, 30, 60 and 120 min post injection.
In the insulin tolerance tests, male Fh1aKOmice and control littermates were fasted for 3-4 hr prior to the experiments. Fast-acting
human insulin (0.75 U/kg Actrapid, Novo Nordisk) was injected intraperitoneally with a 25gauge needle at time zero and samples
taken for plasma glucose measurements after 15, 30, 60 and 120 min post injection.
Imaging of Cytosolic ATP/ADP, Ca2+, Na+ and pH in Mouse a-Cells
For these experiments, the extracellular medium consisted of (mM) 140 NaCl, 4.6 KCl, 2.6 CaCl2, 1.2 MgCl2, 1 NaH2PO4, 5 NaHCO3,
10 HEPES, (pH 7.4, with NaOH) and (unless otherwise stated) 1 glucose. When extracellular Na+ was lowered to 10 mM, NaCl was
equimolarly replaced by N-methyl-D-glucamine. For measurements of [Na+]i, the membrane potential was held at z-70 mV by
including the KATP channel activator diazoxide (0.2 mM) in the superfusion medium. The bath was perifused at 60-200 ml/min and
the temperature kept at 34C.
Time-lapse imaging of ATP/ADP ratio in islets was performed using a Zeiss AxioZoom.V16 zoom microscope, and magnifications
between 10x and 14x. Mouse islets were transduced with an adenovirus (33104 infectious units per islet) delivering Perceval, a re-
combinant sensor of ATP/ADP based on circularly permutated YFP variant Venus (Berg et al., 2009). Perceval is pH-sensitive but the
changes in pHi account for <10% of the glucose-induced changes in Perceval fluorescence (Tarasov et al., 2012). Groups of islets
isolated from littermate control and Fh1bKO animals were imaged simultaneously 24 hr post-infection, with single-cell resolution.
Time-lapse imageswere collected every 30 s. The a-cells were identified by the ability of adrenaline to increase cAMP in cells infected
with ‘red downward cADDis’ cAMP recombinant sensor delivered using a BacMam vector.
Parallel time-lapse imaging of [Ca2+]i and pHi in mouse islets was performed on an inverted Zeiss AxioVert 200 microscope
equipped with Zeiss 510-META laser confocal scanning system, using 40x/1.3 objective. Cells that generate spontaneous [Ca2+]i
oscillations at low glucose were taken to represent a-cells. Mouse islets were loaded with 6 mM of the Ca2+ sensitive dye Fluo-4
for 90 min before being transferred to a separate solution containing 6 mM of the pH-sensitive dye SNARF-5F for a further 50 min
at room temperature and imaged using an open chamber at 34C. The ratiometric dye SNARF-5F was excited at 543 nm and emis-
sion was collected at 650 nm and 600 nm, which corresponds to the emission maxima of the sensor at pH 9 and pH 6, respectively.
Fluo-4 was excited at 488 nm and imaged at 530 nm. Images were collected at the frequency of 0.03 Hz. The absolute pHi change in
Figure 4 was estimated using a high K+ (140 mM)-nigericin (10 mM)/valinomycin (5 mM) calibration protocol (Tarasov et al., 2012).
Sodium Green time-lapse measurements of [Na+]i were performed in dispersed islet cells, on a Zeiss AxioZoom.V16 zoom micro-
scope, using magnifications in the range 15x-20x. a-cells were distinguished by the positive cAMP response to 10 mM adrenaline
(Vieira et al., 2004) (as described above). Islets were dispersed into a single-cell suspension, which was plated on 0.17mm thick glass
coverslips in 10 ml droplets and left to attach for >2 hr. Multiple droplets, consisting of cells of different genotypes, were plated on the
same coverslip and imaged simultaneously; thus enhancing the statistical power of comparisons. After 24 hr, cells were pre-loaded
with 6 mM of Sodium Green for 30 min and imaged at several locations throughout the coverslip simultaneously. Sodium Green was
excited at 490 nm and emission was collected at 515 nm. Red downward cADDis was excited at 572 nm and the emission was
collected at 629 nm. Image sequences were analyzed (registration, background subtraction, ROI intensity vs time analysis) using
open-source FIJI software (http://fiji.sc/Fiji).
Singular time-lapse recordings of [Ca2+]i were performed in intact freshly isolated mouse islets loaded with 6 mM Fluo-4 at room
temperature (Molecular Probes) for 90 min and imaged using a Zeiss AxioVert 200 microscope equipped with Zeiss 510-META laser
confocal scanning system, using 40x/1.3 objective. A 488 nm argon laser (3% intensity) was used to excite Fluo-4 and emission was
collected at 530 nm, using 512x512 frame scanning mode with a pixel dwell time of 6 ms and a bit depth of 8-bit. Images were
acquired every 3.93 s (0.25 Hz). a-Cells were identified by an increase in [Ca2+]i in response to adrenaline (5 mM) (Hamilton
et al., 2018). For the singular [Ca2+]i recordings, the numerical data was analysed using IgorPro package (Wavemetrics), each trace
was normalised (F/Fo) and baseline/bleach corrected. Partial area under the curve (pAUC) was then calculated by splitting each trace
into 30 s intervals and computing AUC for each interval using trapezoidal integration. pAUC points falling within a given region (e.g.
1 mM glucose) for each trace were averaged, the mean of these values across the a-cell population was then calculated to generate
the final pAUC value (displayed in the column plot). Statistical analysis was performed using SPSS. Mann-Whitney U-test or Wilcox-
on’s paired test were used to compute the significance of difference between independent and dependent samples, respectively.
Differences with p < 0.05 were considered significant.
Immunohistochemistry and Immunofluorescence: Mouse, Rat and Human Pancreatic Tissue
Mouse and human pancreases were fixed in 10% neutral-buffered formalin, dehydrated and processed for paraffin wax embedding
and sectioning (3 mm). Immunohistochemistry (IHC) was carried out using the EnVision kit (Dako) as per the manufacturer’s protocol
with the following antibodies: FH, insulin, glucagon and 2SC (Nagai et al., 2007).
Immunofluorescence was performed using the same antibodies as for IHC with Alexa Fluor secondary antibodies using a Zeiss
LSM510 META confocal imaging system.
Both staining and analysis of murine and human pancreatic sections were conducted blinded. Sections from human subjects were
scored by 3 independent observers.Cell Metabolism 29, 430–442.e1–e4, February 5, 2019 e3
Fumarase Activity Measurements
Fumarase activity was determined by measuring the rate of NADH production from the coupled reaction converting fumarate to
oxaloacetate via malate dehydrogenase (MDH) as described previously (Massey, 1953). pH-dependent changes in fumarase
were measured on 0.05 U of porcine fumarase by adjusting the pH of the HEPES buffer using KOH. A 5 ml sample was loaded in
a 96-well plate, 195 ml assay buffer (50 mM Hepes-KOH, 1 mM KH2PO4, 1 mM MgCl2, 10 mM NAD
+, 10 mM L-glutamate, 6.75 U
malate dehydrogenase, 2.5 U glutamate-oxaloacetate transaminase) was added and the plate was incubated for 10 min at 37C.
Following the incubation, 10 ml of 30 mM fumarate (Sigma) was added and the appearance of NADH was measured every 30 s at
37C by excitation/emission at 360/450 nm (Enspire, 2300 Multilabel Reader, Perkin Elmer). NADH concentration was determined
from a standard curve. All samples were run in triplicate and normalized to protein content, asmeasured by bicinchoninic acid protein
assay.
Sglt Expression Analysis
Total RNA frommouse tissues was isolated using a combination of TRIzol and PureLink RNAMini Kit. DNase treatment was included
to eliminate DNA contamination. cDNA was synthesized using the High Capacity RNA-to-cDNA kit. Real-time qPCR was performed
using SYBR Green detection and gene specific QuantiTect Primer Assay. Relative expression was calculated as 2-DDCT. Actb and
Ppia were used for normalization.
Electrophysiological Measurements
Electrical activity measurements were conducted as previously described (Zhang et al., 2013). Briefly, membrane potential of islet
cells was monitored in islet cells within freshly isolated intact mouse islets using perforated patch whole-cell technique carried
out at 32–34C. The recording was performed using an EPC-10 patch-clamping amplifier (HEKA Electronics, Lambrecht/Pfalz, Ger-
many) and Pulse (version 8.80) software. Patch pipettes were pulled fromborosilicate glasswith the resistances of5MWwhen filled
with the pipette solutions. The pipette solution contains (mM): 76 K2SO4, 10 NaCl, 10 KCl, 1 MgCl2 and 5 HEPES (pH 7.35 with KOH)
and the extracellular solution consists of (mM): 140 NaCl, 3.6 KCl, 0.5 MgSO4, 1.5 CaCl2, 0.5 NaH2PO4, 5 NaHCO3 and 10 HEPES
(pH 7.4 with NaOH). Glucose concentrations are as indicated in the figure. Amphotericin B (0.24 mg/ml) was included in the pipette
solution for membrane perforation. Data analysis was performed using ClampFit (Version 9.2.0.11, Molecular Devices).
Human Islets and Ethics
Human pancreatic islets were isolated, with ethical approval and clinical consent, at the Diabetes Research andWellness Foundation
Human islet Isolation Facility (Oxford). For histology, pancreatic tissue blocks from the Oxford Human Pancreas Repository were
used (licensed by the Human Tissue Authority).
Hormone Secretion from Human Islets
Human islets from three donors (2 female and 1 male; age: 52.33±0.8; BMI: 30±2; HbA1c: 5.6-5.7%) were cultured in RPMI-1640
(supplemented with 10%FCS and 1%penicillin and streptomycin) containing 5mMglucose. Secretion experiments were performed
as described above.
QUANTIFICATION AND STATISTICAL ANALYSIS
All data are presented as mean ± standard error of mean (SEM) of the indicated number of experiments (n). All statistical tests were
conducted in Prism5 (GraphPad Software, San Diego, CA). For two groupings, a t-test was conducted with the appropriate post-hoc
test. For more than two groupings, a one-way ANOVA was performed. If the data passed normality criteria (D’Agostino’s test of
normality and Bartlett’s test of equal variances) a parametric test was conducted with the appropriate post-hoc test (Student
Newman-Keuls). If the normality criteria were not met, a Kruskal–Wallis test with Dunn’s multiple comparison test was conducted.
Levels of significance are given in the figures for the indicated comparisons.
For analysis of imaging data, statistical significance of the differences between paired or unpaired samples were tested using
Friedman or Kruskall-Wallis tests, respectively, with Nemenyi post-hoc analysis, as implemented in R package (R Development
Core Team, 2016).e4 Cell Metabolism 29, 430–442.e1–e4, February 5, 2019
